Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings

Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings

Background: Trastuzumab deruxtecan (T-DXd) has been approved for a third- or later-line treatment of HER2-positive advanced gastric cancer (AGC) in Japan. However, clinical data on the use of T-DXd in real-world practice remain insufficient. Although early tumor shrinkage (ETS) serves as an early on...

Full description

Saved in:
Bibliographic Details
Main Authors: Koshiro Fukuda, Hiroki Osumi, Keitaro Shimozaki, Keisho Chin, Mariko Ogura, Shota Fukuoka, Shohei Udagawa, Koichiro Yoshino, Mikako Tamba, Takeru Wakatsuki, Eiji Shinozaki, Kensei Yamaguchi, Akira Ooki
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848251333538
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items